Heme

Andrew MorenoAnemia | May 23, 2024
Before performing allogeneic HSCT in AA patients, clinicians should measure ANC as a prognostic factor.
Read More
Andrew MorenoSickle Cell Disease | May 22, 2024
The REACH trial’s findings suggest a reduced burden upon transfusion resources worldwide is possible.
Leah LawrenceHemophilia | May 21, 2024
Patients with hemophilia A who received prophylaxis had a reduced risk for ICH.
Leah LawrenceHemophilia | May 14, 2024
Analysis shows pharmacokinetic-guided dosing may be effective for guiding prophylactic factor concentrate therapy.
Leah LawrenceHemophilia | May 14, 2024
Compared with before surgery, the percentage of factor VIII increase was 42.9% at day one and 36.4% on day two.
Leah LawrenceHemophilia | May 10, 2024
Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia.
Melissa BadamoSickle Cell Disease | May 8, 2024
The gene therapy, which costs $3.1 million, was approved by the FDA in December 2023.
Patrick DalySickle Cell Disease | May 2, 2024
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
Melissa BadamoSickle Cell Disease | May 2, 2024
Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.
Patrick DalyHemophilia | April 29, 2024
The US FDA has approved fidanacogene elaparvovec-dzkt, a gene therapy for adults with hemophilia B.
Patrick DalyAnemia | April 26, 2024
Oral and intravenous iron supplementation effectively treated restless legs syndrome in patients with iron deficiency anemia.
Melissa BadamoSickle Cell Disease | April 26, 2024
In the one-year, fixed-dose extension period of the ESTIMATE study, mitapivat showed continued safety and efficacy in SCD.
Patrick DalySickle Cell Disease | April 23, 2024
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Patrick DalySickle Cell Disease | April 23, 2024
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Patrick DalySickle Cell Disease | April 19, 2024
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
Melissa BadamoSickle Cell Disease | April 18, 2024
The study compared health care resource use and costs of pediatric patients with SCD compared with matched controls.
Patrick DalyAnemia | April 17, 2024
Intravenous iron was safe and effective in pediatric patients with iron deficiency anemia and inflammatory bowel disease.
Patrick DalyAnemia | April 15, 2024
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
Yaw Ansong-Ansongton, MDSickle Cell Disease | April 12, 2024
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
Yaw Ansong-Ansongton, MDSickle Cell Disease | April 9, 2024
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
Advertisement
Advertisement
Latest News

May 29, 2024